A presentation at the 2026 ONA Summit described the role of oncology nurses in managing the care of patients with NF-1 and PN undergoing treatment with MEK inhibitors.
BRAF and MEK inhibitors are effective in treating resectable melanoma with BRAF V600 mutations, achieving significant pathological responses. The combination therapy significantly improves ...
Targeted BRAF-MEK inhibition resulted in a response in nearly all patients with untreated BRAF V600E–mutated papillary craniopharyngioma, according to results from a small phase II study. Of 16 ...
A phase 1b/2 trial of pepinemab and avelumab as second line therapy for patients with metastatic pancreatic adenocarcinoma. This is an ASCO Meeting Abstract from the 2024 ASCO Gastrointestinal Cancers ...
The cDNAs encoding RAF1 mutants were generated by PCR and inserted into pCDNA3.1(+) vector with N-terminal FLAG tag. Plasmids were transfected into 293T cells by using lipofectamine 2000 (Invitrogen), ...
Until now, the early phase of drug discovery for the development of new therapeutics has been both cost- and time-intensive. Researchers at KIT (Karlsruhe Institute of Technology) have now developed a ...
HT-MEK—short for High-Throughput Microfluidic Enzyme Kinetics—combines microfluidics and cell-free protein synthesis technologies to dramatically speed up the study of enzymes. Credit: Daniel Mokhtari ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results